Presented by Avaí Bio Inc: AVAI just flipped the switch from story to execution, and its anti-aging platform is entering a phase to take a deeper look…

The Magnificent Seven earnings gauntlet is splitting the tape clean down the middle this morning. One hyperscaler delivered the cloud number investors have been begging to see. Another announced a capital expenditure plan so large it's pulling the stock down nearly double digits.

The pattern beneath that split is the question dominating premarket: when does AI spending stop being a story about ambition and start being a story about returns? Outside the megacaps, a chipmaker, a used car retailer, and a weight-loss drug giant are all delivering the cleanest version of that answer.

Momentum is building at Avaí Bio, Inc. (OTCQB: AVAI). With its new Master Cell Bank now in production—developed alongside Austrianova—the company is taking a critical step toward scaling its α-Klotho program, a therapy aimed at restoring a key protein tied to aging and disease. 

In simple terms: this is where biotech ideas start turning into something real, repeatable, and potentially commercial.

Investors looking for early exposure to big trends should take note. Longevity science, regenerative medicine, and cell therapy are all converging—and AVAI is sitting right at that intersection with a platform built to target multiple high-value conditions. 

It’s still early, but that’s exactly the point: this is the stage where positioning happens before momentum becomes obvious. The convergence of aging, chronic disease, and biotech innovation creates a powerful backdrop for AVAI’s platform.

Carvana (CVNA): 9.5%

The online used car marketplace told investors to expect record retail unit sales and adjusted EBITDA in Q2. After years of being viewed as a binary turnaround story, Carvana is beginning to look like a company that consistently delivers.

Qualcomm (QCOM): +9.1%

The chipmaker is leading premarket gainers after a clean earnings beat. In a sector where AI capex concerns are dominating the conversation, a straightforward profit beat from a non-hyperscaler chip name is exactly the kind of story the market wants right now.

Alphabet (GOOGL): +7.7%

Cloud is the story. Google Cloud revenue surged 63% year-over-year and crushed expectations, giving investors the one thing they wanted to see from a hyperscaler this earnings season: actual returns on the AI capex bill.

Eli Lilly (LLY): +6.8%

The Zepbound and Mounjaro maker blew past expectations and raised its full-year sales outlook. GLP-1 demand is still the most powerful single trend in pharma, and Lilly just told the market it's ramping faster than analysts thought.

Royal Caribbean (RCL): +5.8%

The cruise operator beat on earnings even as revenue came in just shy of consensus. Demand for cruises continues to defy every recession call thrown at it, and the print reinforces that consumers are still spending.

Meta Platforms (META): -9.4%

The Facebook parent hiked its full-year capex guidance to a range of $125 to $145 billion, and investors are not happy about the bill. A solid Q1 beat couldn't compete with a number that big, and the market is once again asking when the AI spending pays back.

Teladoc Health (TDOC): -9.2%

The telemedicine company posted a wider-than-expected loss, even as revenue topped estimates. Teladoc has been trying to convince the market it has a path to profitability, and a worse loss undercuts that case.

KLA Corp (KLAC): -5.0%

Guidance disappointed. The wafer fabrication equipment maker has been a quiet AI infrastructure play, but the next quarter's outlook came in soft enough to make investors question whether the chip equipment cycle is still pacing with the rest of the AI complex.

Equinix (EQIX): -3.2%

The data center operator raised its 2026 forecast, but not enough. Analysts had been positioned for stronger growth, and a guidance bump that came in below the high end of expectations counts as a miss in a sector priced for AI-fueled acceleration.

AVAI Is Moving Fast in the Longevity Race—And This Klotho Breakthrough Could Be the Early Signal Investors Don’t Want to Miss

Avaí Bio, Inc. (OTCQB: AVAI) just hit a key inflection point—launching GMP production of its Master Cell Bank for its α-Klotho anti-aging program with Austrianova. That may sound technical, but here’s what it really means: the company is stepping out of concept mode and into real-world production infrastructure. 

By building the foundation required to scale a “longevity protein” therapy, AVAI) is positioning itself in one of biotech’s hottest frontiers—treating aging and chronic disease at the biological level, not just managing symptoms.

This isn’t a niche opportunity. Aging, diabetes, and chronic disease represent massive, trillion-dollar global markets—and AVAI is developing a platform designed to plug directly into that demand with long-term, cell-based solutions. Early-stage biotech is always high risk, but it’s also where the biggest upside lives—and this kind of milestone is not to be overlooked! 

AVAI isn’t just chasing trends—it’s building within some of the largest markets in global healthcare.

Axsome Therapeutics (AXSM)

Today is the FDA's PDUFA action date for Axsome's supplemental application to expand AXS-05 (already approved as Auvelity for major depression) into Alzheimer's disease agitation. Retail traders on Stocktwits have been positioning around the date for weeks, with the company's page showing message volume flagged as "high" against a bullish tilt.

Axsome has already doubled its salesforce in anticipation of the indication, which management estimates covers roughly five million patients with limited approved options. An approval would validate that buildout, while a delay or a complete response letter would leave the cost structure exposed. The decision could land at any point today.

✌️That’s it for today.